Mino-Lok is a small molecule commercialized by Citius Pharmaceuticals, with a leading Phase III program in Fungal Infections. According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Mino-Lok’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Mino-Lok is expected to reach an annual total of $249 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Mino-Lok Overview
Mino-Lok is under development for the treatment of unspecified infectious diseases (catheter-related bloodstream infections (CRBSIs)) caused by Staphylococcus epidermidis, Staphylococcus aureus, Candida spp and Pseudomonas aeruginosa. It is administered through intravenous route in the form of solution. The drug candidate consists of minocycline, edetate (disodium EDTA) and ethyl alcohol. It is developed based on the lock solution technology.
Citius Pharmaceuticals Overview
Citius Pharmaceuticals (Citius) is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care and critical care drug products. The company’s proprietary product candidates include Mino-Lok, an antibiotic lock solution intended for the treatment of patients with catheter-related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine intended to provide anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. Citius is headquartered in Cranford, New Jersey, the US.
The operating loss of the company was US$33.2 million in FY2023, compared to an operating loss of US$33.3 million in FY2022. The net loss of the company was US$32.5 million in FY2023, compared to a net loss of US$33.6 million in FY2022.
For a complete picture of Mino-Lok’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
